Matt Kapusta, uniQure CEO

UniQure cash­es out $10M up­front to get can­di­date for in­her­it­ed ALS

Gene ther­a­py play­er uniQure has signed a new agree­ment with Apic Bio for its ALS gene ther­a­py.

The biotech said Tues­day morn­ing that it now has a glob­al li­cens­ing deal with Apic for APB-102, a gene ther­a­py can­di­date for a rare form of the dis­ease called su­per­ox­ide dis­mu­tase 1 amy­otroph­ic lat­er­al scle­ro­sis, or SOD1 ALS.

SOD1 ALS is the same dis­ease sub­set Bio­gen’s drug tofersen is at­tempt­ing to treat. Bio­gen sub­mit­ted tofersen for ac­cel­er­at­ed ap­proval last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.